SMS Lifesciences India Limited (SMSLIFE) - Total Liabilities

Latest as of September 2025: Rs1.71 Billion INR ≈ $18.54 Million USD

Based on the latest financial reports, SMS Lifesciences India Limited (SMSLIFE) has total liabilities worth Rs1.71 Billion INR (≈ $18.54 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of SMS Lifesciences India Limited to assess how effectively this company generates cash.

SMS Lifesciences India Limited - Total Liabilities Trend (2016–2025)

This chart illustrates how SMS Lifesciences India Limited's total liabilities have evolved over time, based on quarterly financial data. Check SMS Lifesciences India Limited (SMSLIFE) liquid assets ratio to evaluate the company's liquid asset resilience ratio.

SMS Lifesciences India Limited Competitors by Total Liabilities

The table below lists competitors of SMS Lifesciences India Limited ranked by their total liabilities.

Company Country Total Liabilities
Lotte Chilsung Beverage Co Ltd
KO:005305
Korea ₩2.81 Trillion
374Water Inc. Common Stock
NASDAQ:SCWO
USA $4.87 Million
3I Infrastructure PLC
LSE:3IN
UK GBX387.00 Million
Nirvana Daii Public Company Limited
BK:NVD
Thailand ฿9.41 Billion
Exel Composites Oyj
HE:EXL1V
Finland €61.14 Million
Osangjaiel Co. Ltd
KQ:053980
Korea ₩36.21 Billion
Ta Jiang Co Ltd
TW:1453
Taiwan NT$1.48 Billion
TPBI PCL
BK:TPBI
Thailand ฿1.17 Billion

Liability Composition Analysis (2016–2025)

This chart breaks down SMS Lifesciences India Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see SMS Lifesciences India Limited (SMSLIFE) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.06 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.83 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.44 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how SMS Lifesciences India Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for SMS Lifesciences India Limited (2016–2025)

The table below shows the annual total liabilities of SMS Lifesciences India Limited from 2016 to 2025.

Year Total Liabilities Change
2025-03-31 Rs1.78 Billion
≈ $19.24 Million
-9.62%
2024-03-31 Rs1.97 Billion
≈ $21.29 Million
+13.57%
2023-03-31 Rs1.73 Billion
≈ $18.75 Million
-9.62%
2022-03-31 Rs1.92 Billion
≈ $20.74 Million
+10.83%
2021-03-31 Rs1.73 Billion
≈ $18.72 Million
+26.25%
2020-03-31 Rs1.37 Billion
≈ $14.83 Million
-16.21%
2019-03-31 Rs1.64 Billion
≈ $17.70 Million
+85.41%
2018-03-31 Rs882.47 Million
≈ $9.54 Million
-8.06%
2017-03-31 Rs959.82 Million
≈ $10.38 Million
-7.01%
2016-03-31 Rs1.03 Billion
≈ $11.16 Million
--

About SMS Lifesciences India Limited

NSE:SMSLIFE India Biotechnology
Market Cap
$42.13 Million
Rs3.90 Billion INR
Market Cap Rank
#22513 Global
#1255 in India
Share Price
Rs1288.50
Change (1 day)
-6.64%
52-Week Range
Rs1078.80 - Rs1453.00
All Time High
Rs1747.88
About

Haleos Labs Limited engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India. The company offers API and intermediates in areas, such as anti-ulcer, anti-migraine, anti-hypertensive, erectile dysfunction, anti-cancer, antifungal, anti-obesity, anti-emetic, anti-depressant, anti-worm, anti-infective, anti-gout, anti-convulsant, antiviral, and anesthesia, a… Read more